
Manuel Mendizabal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5758722/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2011, 9, 36-41.e1.	2.4	422
2	Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: A multicenter prospective study. Journal of Hepatology, 2015, 62, 1056-1060.	1.8	108
3	Liver transplantation in patients with cystic fibrosis: Analysis of united network for organ sharing data. Liver Transplantation, 2011, 17, 243-250.	1.3	75
4	Treatment with directâ€acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma. Liver International, 2019, 39, 1033-1043.	1.9	65
5	Liver transplantation in acute liver failure: A challenging scenario. World Journal of Gastroenterology, 2016, 22, 1523.	1.4	63
6	Efficacy and safety of long term entecavir in chronic hepatitis B treatment naÃ ⁻ ve patients in clinical practice. Annals of Hepatology, 2014, 13, 327-336.	0.6	59
7	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. Journal of Hepatology, 2021, 75, 1026-1033.	1.8	59
8	Liver injury after SARSâ€CoVâ€2 vaccination: Features of immuneâ€mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology, 2022, 76, 1576-1586.	3.6	58
9	Outcome of COVIDâ€19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology, 2021, 73, 2099-2109.	3.6	56
10	Current Management of Hepatocellular Carcinoma. Medical Clinics of North America, 2009, 93, 885-900.	1.1	53
11	A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma. Annals of Hepatology, 2019, 18, 480-487.	0.6	50
12	Fulminant presentation of autoimmune hepatitis. European Journal of Gastroenterology and Hepatology, 2015, 27, 644-648.	0.8	49
13	Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents. Clinical Gastroenterology and Hepatology, 2020, 18, 2554-2563.e3.	2.4	48
14	Changing etiologies and outcomes of acute liver failure: Perspectives from 6 transplant centers in Argentina. Liver Transplantation, 2014, 20, 483-489.	1.3	33
15	Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. Journal of Viral Hepatitis, 2017, 24, 442-453.	1.0	31
16	Relapse rates in chronic hepatitis <scp>B</scp> naÃ⁻ve patients after discontinuation of antiviral therapy with entecavir. Journal of Viral Hepatitis, 2014, 21, 590-596.	1.0	27
17	Impact of Public Health Policies on Alcoholâ€Associated Liver Disease in Latin America: An Ecological Multinational Study. Hepatology, 2021, 74, 2478-2490.	3.6	27
18	Noncirrhotic portal hypertension: Another cause of liver disease in HIV patients. Annals of Hepatology, 2009, 8, 390-395.	0.6	26

MANUEL MENDIZABAL

#	Article	IF	CITATIONS
19	Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety, 2016, 15, 1463-1475.	1.0	26
20	Effects of immunosuppressive drugs on COVIDâ€19 severity in patients with autoimmune hepatitis. Liver International, 2022, 42, 607-614.	1.9	26
21	Prospective Latin American cohort evaluating outcomes of patients with COVID-19 and abnormal liver tests on admission. Annals of Hepatology, 2021, 21, 100298.	0.6	25
22	Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. International Journal of Clinical Practice, 2011, 65, 866-870.	0.8	21
23	When the Creation of a Consortium Provides Useful Answers: Experience of The Latin American DILI Network (LATINDILIN). Clinical Liver Disease, 2019, 13, 51-57.	1.0	21
24	Herbal and Dietary Supplements-Induced Liver Injury in Latin America: Experience From the LATINDILI Network. Clinical Gastroenterology and Hepatology, 2022, 20, e548-e563.	2.4	21
25	Overcoming barriers to hepatitis C elimination. Frontline Gastroenterology, 2019, 10, 207-209.	0.9	20
26	Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Annals of Hepatology, 2021, 24, 100321.	0.6	19
27	Changing Etiologies and Prognostic Factors in Pediatric Acute Liver Failure. Liver Transplantation, 2020, 26, 268-275.	1.3	16
28	Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection. Annals of Hepatology, 2021, 25, 100350.	0.6	16
29	Liver transplantation in adults with acute liver failure: Outcomes from the Argentinean Transplant Registry. Annals of Hepatology, 2019, 18, 338-344.	0.6	14
30	Postâ€ŧransplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience. Clinical Transplantation, 2013, 27, E469-77.	0.8	13
31	Neurological events after liver transplantation: a single-center experience. Transplant International, 2014, 27, 1244-1252.	0.8	13
32	Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCVâ€infected patients in realâ€ife cohort from Latin America. Journal of Medical Virology, 2017, 89, 1590-1596.	^a 2.5	13
33	B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin. Journal of Viral Hepatitis, 2019, 26, 1200-1209.	1.0	13
34	ls recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? Towards a predictive recurrence score. Annals of Hepatology, 2014, 13, 211-218.	0.6	12
35	The ECHO model proved to be a useful tool to increase clinicians' selfâ€effectiveness for care of patients with Hepatitis C in Argentina. Journal of Viral Hepatitis, 2019, 26, 1284-1292.	1.0	12
36	Noncirrhotic portal hypertension: another cause of liver disease in HIV patients. Annals of Hepatology, 2009, 8, 390-5.	0.6	10

MANUEL MENDIZABAL

#	Article	IF	CITATIONS
37	Isolated Intrapulmonary Vascular Dilatations and the Risk of Developing Hepatopulmonary Syndrome in Liver Transplant Candidates. Annals of Hepatology, 2017, 16, 548-554.	0.6	9
38	Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1419-1431.	1.1	9
39	LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Annals of Hepatology, 2020, 19, 662-667.	0.6	9
40	Directâ€Acting Antivirals and Hepatocellular Carcinoma: No Evidence of Higher Waitâ€List Progression or Posttransplant Recurrence. Liver Transplantation, 2020, 26, 640-650.	1.3	9
41	Incidence, risk factors, and outcomes related with neurological events after liver transplantation in adult and pediatric recipients. Pediatric Transplantation, 2018, 22, e13159.	0.5	8
42	Asterixis. New England Journal of Medicine, 2010, 363, e14.	13.9	7
43	Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. Hemodialysis International, 2018, 22, S97-S103.	0.4	7
44	A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management. Annals of Hepatology, 2020, 19, 396-403.	0.6	7
45	Serious liver injury induced by Nimesulide: an international collaborative study. Archives of Toxicology, 2021, 95, 1475-1487.	1.9	7
46	Hepatitis C Virus Infection: What Are We Currently Doing in Latin America About WHO's Proposals for 2030?. Clinical Liver Disease, 2021, 18, 72-75.	1.0	7
47	Idiosyncratic Drug-Induced Acute Liver Failure: A Challenging and Distressing Scenario. Current Drug Safety, 2019, 14, 94-101.	0.3	7
48	Successful orthotopic liver transplantation and delayed delivery of a healthy newborn in a woman with fulminant hepatic failure during the second trimester of pregnancy. Annals of Hepatology, 2014, 13, 288-292.	0.6	6
49	Predicting early discharge from hospital after liver transplantation (ERDALT) at a single center: a new model. Annals of Hepatology, 2015, 14, 845-855.	0.6	5
50	Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities. Liver Transplantation, 2017, 23, 1210-1215.	1.3	5
51	Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Realâ€world experience from HCVâ€LALREAN cohort. Journal of Medical Virology, 2020, 92, 3545-3555.	2.5	4
52	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrologia, 2020, 40, 46-52.	0.2	3
53	Outbreak of hepatitis A in a post-vaccination era: High rate of co-infection with sexually transmitted diseases. Annals of Hepatology, 2020, 19, 641-644.	0.6	3
54	Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting. Journal of Viral Hepatitis, 2020, 27, 1430-1436.	1.0	3

MANUEL MENDIZABAL

#	Article	IF	CITATIONS
55	Hepatitis E infection is an infrequent cause of acute hepatitis in the metropolitan area of Buenos Aires. Journal of Clinical Virology, 2020, 126, 104309.	1.6	3
56	â€~Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant. Annals of Hepatology, 2021, 25, 100337.	0.6	3
57	Characteristics of Liver Transplantation in Argentina: A Multicenter Study. Transplantation Proceedings, 2018, 50, 478-484.	0.3	2
58	Acute liver failure: Do the EASL guidelines address the whole spectrum?. Journal of Hepatology, 2018, 68, 843.	1.8	2
59	The genetic variability of hepatitis B virus subgenotype F1b precore/core gene is related to the outcome of the acute infection. Virus Research, 2020, 277, 197840.	1.1	2
60	ls recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? towards a predictive recurrence score. Annals of Hepatology, 2014, 13, 211-8.	0.6	2
61	Domino liver graft with hepatocellular carcinoma used as bridge therapy for a patient with acute liver failure: A case report. Liver Transplantation, 2014, 20, 386-387.	1.3	1
62	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. Nefrologia, 2020, 40, 46-52.	0.2	1
63	Jaundice after allogeneic hematopoietic stem cell transplantation. Hepatology, 2009, 50, 2044-2045.	3.6	Ο
64	Management of HBV, HCV, and HDV coinfection. Current Hepatitis Reports, 2009, 8, 111-118.	0.3	0
65	Preface: A CLD Collaboration With the Latin American Association for the Study of the Liver (ALEH). Clinical Liver Disease, 2019, 13, 35-35.	1.0	0
66	FRI-078-Serious liver injury induced by nimesulide: An international collaboration reporting 57 cases. Journal of Hepatology, 2019, 70, e418-e419.	1.8	0
67	Su1537 – Non-Variceal Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis: Clinical Features, Endoscopic Findings and Mortality. Gastroenterology, 2019, 156, S-566.	0.6	0
68	Directâ€acting antiviral treatment failure in genotype 2 hepatitis C chronic infection. Journal of Viral Hepatitis, 2021, 28, 446-447.	1.0	0
69	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 623-624.	2.4	0
70	The Course of Renal Function in Patients on Mesalamine Therapy with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2009, 104, S449.	0.2	0
71	Certolizumab Pegol as Salvage Therapy in Patients with CD Intolerant to or Without Adequate Response to Two Prior Anti-TNF Agents. American Journal of Gastroenterology, 2009, 104, S450.	0.2	0
72	Does Use of Video Capsule Endoscopy in Patients With Known or Suspected Inflammatory Bowel Disease Change their Management?. American Journal of Gastroenterology, 2009, 104, S437.	0.2	0

#	Article	IF	CITATIONS
73	A Meta-analysis of GI complications in Common Variable Immune Deficiency (CVID). American Journal of Gastroenterology, 2009, 104, S437.	0.2	0
74	Elderly Donors in Transplantation. , 2011, , 1321-1333.		0
75	Liver transplant outcomes during the COVID-19 pandemic. Annals of Hepatology, 2022, 27, 100656.	0.6	0
76	Quantitative HBsAg an unreliable marker for diagnosis and disease progression in genotype F chronic HBeAgâ€negative infections. Journal of Viral Hepatitis, 2022, 29, 298-301.	1.0	0